Integrated Biopharma Alpha and Beta Analysis
| INBPDelisted Stock | USD 0.33 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Integrated Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Integrated Biopharma over a specified time horizon. Remember, high Integrated Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Integrated Biopharma's market risk premium analysis include:
Beta (0.26) | Alpha (0.11) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Integrated |
Integrated Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Integrated Biopharma market risk premium is the additional return an investor will receive from holding Integrated Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Integrated Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Integrated Biopharma's performance over market.| α | -0.11 | β | -0.26 |
Integrated Biopharma Fundamentals Vs Peers
Comparing Integrated Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Integrated Biopharma's direct or indirect competition across all of the common fundamentals between Integrated Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Integrated Biopharma or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Integrated Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Integrated Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Integrated Biopharma to competition |
| Fundamentals | Integrated Biopharma | Peer Average |
| Return On Equity | 0.13 | -0.31 |
| Return On Asset | 0.0336 | -0.14 |
| Profit Margin | 0.04 % | (1.27) % |
| Operating Margin | 0.03 % | (5.51) % |
| Current Valuation | 12.05 M | 16.62 B |
| Shares Outstanding | 29.95 M | 571.82 M |
| Shares Owned By Insiders | 68.58 % | 10.09 % |
Integrated Biopharma Opportunities
Integrated Biopharma Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Integrated Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Integrated or other otcs. Alpha measures the amount that position in Integrated Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Integrated Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Integrated Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Integrated Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Integrated Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Integrated Biopharma. Please utilize our Beneish M Score to check the likelihood of Integrated Biopharma's management manipulating its earnings.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Integrated Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |